BioInformant

Your Global Leader in Stem Cell Market Research

CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank

By Leave a Comment

CytoMed Therapeutics Seeks to Advance Cord Blood-Derived Therapies For Auto-immune Diseases and Cancers
Long-term intention is to spin off LongevityBank as standalone biotech, offering immune cell banking and scalable NK/T cell platforms.

SINGAPORE, Aug. 28, 2025 — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, has successfully expanded clinical-scale natural killer (“NK”) cells from cord blood units that have been cryopreserved for more than a decade. This sets the impetus for establishing a new business platform to generate additional revenue streams and future growth. [Read more…]

Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip

By Leave a Comment

Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials
Mytos’ iDEM platform replaces traditional iPSC manufacturing with a closed, automated system that delivers consistent, GMP-ready cells while reducing cost, variability, and time to clinic
Collaborations highlight the versatility of Mytos’ iDEM platform across diverse cell types and clinical applications from blindness and hearing loss to complex bone regeneration

[Read more…]

Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production

By Leave a Comment

September 24, 2025 – Takara Bio Europe announces the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs).

MSC-derived EVs are increasingly recognized as next-generation, cell-free therapeutic candidates, offering regenerative and immunomodulatory benefits without the safety concerns associated with administering intact MSCs. As the field shifts from MSC-based approaches to MSC-EVs, researchers are seeking solutions that deliver both robust yields and reproducible quality at scale. [Read more…]

Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research

By Leave a Comment

LEIDEN, Netherlands — Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment, today announced the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys. New Ncyte® NHP-C vCardiomyocytes provide a scalable, ethical and translational tool for cross-species cardiac studies. [Read more…]

Frequently Asked Questions about Induced Pluripotent Stem Cells (iPSCs)

By Leave a Comment

Have you heard about induced pluripotent stem cells (iPS cells), but don’t know exactly what they are and what they can do? If so, read on to learn the answers to frequently asked questions (FAQs) about iPS cells.

In this article:

  1. What Are iPS Cells?
  2. How Are iPS Stem Cells Produced?
  3. What Are the Advantages of iPS Cells Over ES Cells?
  4. Are iPS Cells Similar to Embryonic Stem Cells?
  5. What Are the Risks of iPS Cell Use?
  6. What Are the Challenges in iPS Cell Research?
  7. Do iPS Cells Have the Potential for Medical Applications?

[Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0